F&P Healthcare (FPH): 1H23 Result – Initial Impressions
F&P Healthcare (FPH) reported a 1H23 result at the top end of guidance with NPAT of NZ$95.9m (NZ$85-95m); Revenue of NZ$691m was ahead of guidance...
389 Views
F&P Healthcare: 1H23 Preview — COVID Crunching
Headline numbers were guided in August but we expect F&P Healthcare's (FPH) 1H23 result to show a challenged period highlighting the COVID demand...
358 Views
F&P Healthcare: Checking the Flow — Competitor Updates
Vapotherm's 3Q22 result continues to reinforce the material headwinds being experienced by F&P Healthcare's (FPH) Hospital segment, particularly...
187 Views
F&P Healthcare (FPH): Vapotherm Q3 Result − Negative Read-Through
Vapotherm (VAPO.NYSE), a small, pureplay competitor to FPH’s nasal high flow optiflow product has reported its Q3 result this morning; Overall read...
182 Views
F&P Healthcare: Breathing Rate Slows
F&P Healthcare's 1H23 guidance confirmed our prior view of material earnings risks, however, the magnitude was significantly greater than expected
215 Views